Sensorion Reports 2020 First Half Results; Financial Position Strengthened with Recent $36.5M Capital Raise
MONTPELLIER, FRANCE – Sensorion, a pioneering clinical stage and gene therapy biotech company specializing in the development of novel therapies to treat, prevent and restore within the field of hearing loss disorders, announced its interim annual results as of June 30, 2020 alongside its outlook for 2020. “Sensorion’s landmark gene therapy agreement with Institut Pasteur…
Read MoreSensorion Announces Appointment of Five Renowned Experts to its Scientific Advisory Board
MONTPELLIER, FRANCE — Sensorion, a clinical-stage biotechnology company which specializes in the development of novel therapies to restore, treat and prevent within the field of hearing loss disorders, has announced the appointment of five renowned experts to its Scientific Advisory Board (SAB). Sensorion’s SAB is chaired by Professor Christine Petit, MD, PhD, a globally renowned…
Read MoreSensorion Appoints Former Ablynx CEO, Dr. Edwin Moses, as Chairman of the Board
MONTPELLIER, FRANCE — Sensorion, a clinical-stage biotechnology company which specializes in the development of novel therapies to restore, treat and prevent within the field of hearing loss disorders, has announced the appointment of Edwin Moses, former Chief Executive Officer of Ablynx, as Chairman of its Board of Directors. Edwin brings more than 25 years of…
Read MoreSensorion Announces Positive Preliminary Preclinical Data from Gene Therapy Program
MONTPELLIER, FRANCE — Sensorion, a pioneering clinical-stage biotechnology company which specializes in the development of novel therapies to restore, treat and prevent within the field of hearing loss disorders, announced promising new preliminary data in non-human primates from its ongoing gene therapy program targeting the Otoferlin encoding gene (OTOF). The following results relate to the…
Read MoreCoronavirus Outbreak Contributes to Delays in Sensorion’s Sudden Hearing Loss Phase II Clinical Trial
MONTPELLIER, FRANCE — Sensorion, a clinical-stage biotech company specializing in the development of novel therapies to restore, treat and prevent within the field of hearing loss disorders, has announced updated timelines for the ongoing Phase 2 study of SENS-401 to treat Sudden Sensorineural Hearing Loss (SSNHL). Patient recruitment rates from this trial now indicate the…
Read MoreGene Therapy Expert, Dr. Géraldine Honnet, Appointed as Sensorion’s New Chief Medical Officer
MONTPELLIER, FRANCE — Sensorion, a clinical-stage biotech company which specializes in the development of novel therapies to restore, treat and prevent within the field of hearing loss disorders, has announced the appointment of gene therapy expert Géraldine Honnet MD, as Chief Medical Officer. Géraldine Honnet is a medical doctor and joins from Généthon, where she…
Read MoreSensorion Receives $6.2M in Funding to Support SENS-401 Phase 2 Study in Sudden Sensorineural Hearing Loss
MONTPELLIER, FRANCE — French biotech firm Sensorion has announced that the French government has awarded the PATRIOT consortium a Structuring Research and Development Project for Competitiveness (“Projet de recherche et développement Structurant pour la Compétitivité” – PSPC) non-dilutive funding. The grant will be used to finance the development of SENS-401 in SSNHL, including work by Institut Pasteur to…
Read MoreSensorion Announces Disappointing Results From SENS-111 Phase 2b Trial in Acute Unilateral Vestibulopathy
MONTPELLIER, FRANCE — Biotech firm Sensorion has reported results from a Phase 2 proof-of-concept trial of SENS-111 for the treatment of acute unilateral vestibulopathy (AUV). SENS-111 was reported to be safe and well tolerated. However, it did not meet the primary endpoint of vertigo intensity, measured by the area under the curve of the vertigo…
Read MoreSensorion Announces Poster Presentation of New SENS-401 Preclinical Data at SFN 2019
MONTPELLIER, FRANCE — French biotech firm Sensorion, which specializes in the development of novel therapies to restore, treat and prevent inner ear diseases such as hearing loss, tinnitus and vertigo, announced that it has contributed a poster presentation at the 2019 Annual Meeting of the Society for Neuroscience (SFN 2019) held in Chicago from the…
Read More
Sensorion Receives FDA Investigational New Drug Clearance for Arazasetron (SENS-401)
MONTPELLIER, FRANCE — French biotech firm Sensorion, which specializes in the development of novel therapies to restore, treat and prevent inner ear diseases such as hearing loss, tinnitus and vertigo, announced today that it has received the Investigational New Drug (IND) clearance from the US Food and Drug Administration (FDA) to proceed with SENS-401, based on…
Read More